Key Insights

Highlights

Success Rate

81% trial completion

Published Results

11 trials with published results (16%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.4%

7 terminated out of 67 trials

Success Rate

81.1%

-5.4% vs benchmark

Late-Stage Pipeline

4%

3 trials in Phase 3/4

Results Transparency

37%

11 of 30 completed with results

Key Signals

11 with results81% success

Data Visualizations

Phase Distribution

49Total
Not Applicable (16)
Early P 1 (3)
P 1 (19)
P 2 (8)
P 3 (3)

Trial Status

Completed30
Unknown11
Recruiting10
Terminated7
Active Not Recruiting5
Not Yet Recruiting2

Trial Success Rate

81.1%

Benchmark: 86.5%

Based on 30 completed trials

Clinical Trials (67)

Showing 20 of 20 trials
NCT01736293Active Not RecruitingPrimary

Natural History of Eye Diseases Related to ABCA4 Mutations

NCT01432847Recruiting

Cell Collection to Study Eye Diseases

NCT04545736Phase 1Recruiting

Oral Metformin for Treatment of ABCA4 Retinopathy

NCT02617966RecruitingPrimary

Rod and Cone Mediated Function in Retinal Disease

NCT06455826Phase 1Completed

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

NCT06789445Phase 1Recruiting

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT07269665Early Phase 1Not Yet Recruiting

First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration

NCT07425717Not ApplicableNot Yet RecruitingPrimary

Multicenter Study of Transcranial Magnetic Stimulation on Vision Restoration

NCT04765345Active Not RecruitingPrimary

Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

NCT03846193Phase 1Terminated

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

NCT07174687Phase 2RecruitingPrimary

SGLT2 Inhibitors in Geographic Atrophy

NCT06852963Phase 1Recruiting

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

NCT04129021Not ApplicableRecruiting

High Resolution, High-speed Multimodal Ophthalmic Imaging

NCT06011798Phase 2Completed

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

NCT05797896Active Not Recruiting

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

NCT06167642Enrolling By Invitation

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

NCT06305416Phase 3Recruiting

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

NCT06289452Early Phase 1Active Not Recruiting

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis

NCT05355415RecruitingPrimary

Adaptive Optics Imaging of Outer Retinal Diseases

NCT05921162Enrolling By Invitation

A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

Scroll to load more

Research Network

Activity Timeline